Related Experiment Videos
Molecular analysis of CDKN1C and TP53 in sporadic adrenal tumors
1Department of Medical and Surgical Sciences, Division of Endocrinology, University of Padova, Padova, Italy.
Objective:
To evaluate the roles of the CDKN1C (P57KIP2) gene, which encodes for the cyclin-dependent kinase inhibitor CDNC, and the TP53 tumor suppressor gene in adrenal tumorigenesis, as a means of investigating the molecular basis of sporadic adrenal tumors, which is unknown.
Design:
Screening for the presence CDKN1C and TP53 mutations and analyzing the expression pattern of CDNC, P53 and its downstream effector CDN1 (P21WAF1/CIP1) in a series of 79 sporadic adrenal tumors.
Methods:
Single-strand conformation polymorphism and sequencing were used for mutation analysis of CDKN1C and TP53 in blood and adrenal tissue samples. In a subgroup of 48 tissues, CDKN1C expression was evaluated by RT-PCR and immunohistochemistry. Immunohistochemical analysis of P53 and CDN1 was performed.
Results:
No somatic mutations of CDKN1C were found in the tumors analyzed, in spite of low/absent CDNC expression in adrenocortical adenomas and carcinomas. Mutations in the TP53 gene were present in 70% of adrenocortical carcinomas, associated with abnormal P53 and CDN1 expression, but not in benign neoplasms. In the normal adrenal cortex, CDNC expression was strictly nuclear and confined to the cortical zone (i.e. zona glomerulosa and reticularis), with no staining in the medulla.
Conclusions:
Mutations in the TP53 gene are frequent in adrenocortical carcinomas and might be used as a marker of malignancy. In the normal adrenal cortex, the zone-specific pattern of expression of CDNC suggests a role in adrenal differentiation.
Insights
TP53 gene mutations are common in adrenal carcinomas, serving as a potential malignancy marker. CDKN1C (P57KIP2) gene expression in the normal adrenal cortex suggests a role in adrenal differentiation.
Area of Science:
- Endocrinology
- Molecular Biology
- Oncology
Background:
- The molecular basis of sporadic adrenal tumors remains largely unknown.
- Investigating key genes like CDKN1C (P57KIP2) and TP53 is crucial for understanding adrenal tumorigenesis.
Purpose of the Study:
- To evaluate the roles of the CDKN1C gene and the TP53 tumor suppressor gene in adrenal tumorigenesis.
- To investigate the molecular mechanisms underlying sporadic adrenal tumors.
Main Methods:
- Screening for CDKN1C and TP53 mutations in 79 sporadic adrenal tumors using single-strand conformation polymorphism and sequencing.
- Analyzing the expression of CDKN1C (P57KIP2), P53, and CDN1 (P21WAF1/CIP1) via RT-PCR and immunohistochemistry.
Main Results:
- No somatic mutations in CDKN1C were detected, despite low/absent CDKN1C expression in adrenal adenomas and carcinomas.
- TP53 gene mutations were found in 70% of adrenocortical carcinomas, correlating with abnormal P53 and CDN1 expression.
- CDKN1C exhibited zone-specific nuclear expression in the normal adrenal cortex (zona glomerulosa and reticularis), absent in the medulla.
Conclusions:
- TP53 gene mutations are frequent in adrenocortical carcinomas and may serve as a marker for malignancy.
- The distinct expression pattern of CDKN1C in the normal adrenal cortex suggests its involvement in adrenal differentiation.